Veravas develops the VeraBIND™ technology, which enhances assay sensitivity by eliminating interferences and accurately detecting low-abundance biomarkers across various diseases. This technology enables early detection of critical conditions, such as tau pathology in Alzheimer's disease, improving diagnostic accuracy and patient outcomes.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic assays often struggle to accurately detect low-abundance biomarkers due to interfering substances, which can lead to delayed or inaccurate diagnoses of critical conditions. This limitation hinders early disease detection and can negatively impact patient outcomes across various diseases.
Solution
Veravas has developed VeraBIND, a technology designed to enhance assay sensitivity by eliminating interferences and improving the detection of low-abundance biomarkers. VeraBIND addresses the challenges of accurately diagnosing diseases at an early stage, particularly in conditions like Alzheimer's disease where early detection of tau pathology is crucial. The technology improves sample preparation, providing more accurate and reproducible results, which can accelerate research, facilitate liquid biopsies, and enhance overall test accuracy. By enabling earlier and more reliable detection, VeraBIND aims to improve diagnostic accuracy and ultimately lead to better patient outcomes.
Target Audience
The primary audience includes researchers and diagnostic laboratories focused on early disease detection, biomarker analysis, and improving the accuracy of diagnostic tests.
Features
- VeraBIND technology eliminates interfering substances in assays, enhancing sensitivity for low-abundance biomarkers.
- Focus on early detection of tau pathology associated with Alzheimer's disease.
- Improves sample preparation for more accurate and reproducible results.
- Applicable to a wide range of diseases and sample types.